India's Sun Pharma Advanced Research gains after update on key drugs

Sun Pharma Advanced Research

05/09/2018 07:58

** Shares of Sun Pharma Advanced Research Company
(SPARC) SPRC.NS  rise as much as 4.8 pct to 404.9 rupees,
biggest daily pct gain in nearly a week
    ** Pharma research & development co expects to file with
U.S. Food and Drug Administration its new drug application for
cancer drug Taclantis by Q4 2019, it said https://www.bseindia.com/xml-data/corpfiling/AttachLive/6c4fc0b8-ce6a-49d5-ade6-2390bd3f2bde.pdf
 in a presentation on Tuesday
    ** Co says deadlines for U.S. FDA to review ocular
hypertension drug Xelpros and anti-epileptic agent Elepsia as
Nov 2018 and Jan 2019, respectively
    ** SPARC seems to be nearing monetization of its lead
products, Morgan Stanley says in note
    ** Sun Pharmaceutical Industries  SUN.NS  should benefit
from the potential FY 2019 commercialization of two mid-sized
lead assets (Xelpros and Elepsia XR) - MS
    ** SPARC was demerged from Sun Pharma in 2006, both firms
share same parent
    ** Sun Pharma shares rise as much as 2.5 pct to 671.8 rupees

 ((Reuters Messaging:
tanvi.mehta.thomsonreuters.com@reuters.net))